Case Studies - Nanora Bioscience Corporation, based in California

Case Studies & Scientific Findings

Clinical and Preclinical Validation Goals

Stage 4 Head & Neck Cancer

Stage 4 Head & Neck Cancer:

“Each year, over 900,000 people worldwide are diagnosed with head and neck cancer.”

Stage 4 Lung Cancer

Each year, over 2.2 million people worldwide are diagnosed with lung cancer.

Alzheimer’s Disease Model

Each year, over 2.2 million people worldwide are diagnosed with lung cancer.

Key Outcomes

High-precision gene targeting with minimal toxicity
Significant tumor reduction and therapeutic benefit
Enhanced patient adherence with non-invasive administration.
Targeted and controlled delivery of RNAi therapeutics
Nano-drug delivery technologies.

“Disclaimer:

This website is intended exclusively for accredited investors who have been directly contacted by our team. The information provided on this site is speculative and forward-thinking, reflecting our vision for the future once Nora HNC 1000 is approved. At present, the products and statements discussed have not been clinically tested or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. This site is not a solicitation for investment, and access is restricted to those who have been invited to view

Nanora Bioscience Corporation, based in California, is at the forefront of developing, manufacturing, and commercializing innovative siRNA-based cancer therapeutics. Our mission is to leverage cutting-edge technology to target cancer cells, aiming to inhibit tumor growth and transform cancer treatment with patient-focused solutions.